[Gender-affirming hormone therapy in transgender persons].
Hormonothérapies de transition chez les personnes transgenres.
Journal
Medecine sciences : M/S
ISSN: 1958-5381
Titre abrégé: Med Sci (Paris)
Pays: France
ID NLM: 8710980
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
entrez:
30
11
2022
pubmed:
1
12
2022
medline:
3
12
2022
Statut:
ppublish
Résumé
Medical care for transgender patients is still characterized by an insufficient availability of healthcare services, as well as by poor provider education and training. Transgender patients often require gender-affirming hormone therapy (GAHT), and physicians, including endocrinologists, general practitioners, and others, should be trained to initiate and monitor these treatments throughout the transition process, and beyond. This article will address the specific issues surrounding GAHT in adult transgender women and men. Hormonothérapies de transition chez les personnes transgenres. Aujourd’hui encore, la prise en charge médicale des personnes transgenres pâtit d’une insuffisance d’offre de soins et de formation des soignants. La mise en œuvre d’une hormonothérapie est souvent souhaitée par les personnes transgenres et il est nécessaire qu’un médecin sache l’instaurer et la suivre tout au long de la transition. Nous abordons dans cette revue le traitement hormonal féminisant (THF) chez les femmes transgenres adultes, et le traitement hormonal masculinisant (THM) chez les hommes transgenres adultes.
Autres résumés
Type: Publisher
(fre)
Hormonothérapies de transition chez les personnes transgenres.
Identifiants
pubmed: 36448897
doi: 10.1051/medsci/2022151
pii: msc220224
doi:
Substances chimiques
Hormones
0
Types de publication
English Abstract
Journal Article
Langues
fre
Sous-ensembles de citation
IM
Pagination
905-912Informations de copyright
© 2022 médecine/sciences – Inserm.
Références
Standards de soins. World Professional Association for Transgender Health. https://www.wpath.org/media/cms/Documents/SOC%20v7/SOC%20V7_French.pdf.
Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2017 ; 102 : 3869–3903.
Scheres LJJ, Selier NLD, Nota NM, et al. Effect of gender-affirming hormone use on coagulation profiles in transmen and transwomen. J Thromb Haemost 2021; 19 : 1029–37.
Asscheman H, Giltay EJ, Megens JA, et al. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol 2011 ; 164 : 635–642.
LaVasseur C, Neukam S, Kartika T, et al. Hormonal therapies and venous thrombosis: Considerations for prevention and management. Res Pract Thromb Haemost 2022; 6 : e12763.
Turino Miranda K, Kalenga CZ, Saad N, et al. Gender-affirming estrogen therapy route of administration and cardiovascular risk: a systematic review and narrative synthesis. Am J Physiol Heart Circ Physiol 2022 Sep 2. doi: 10.1152/ajpheart.00299.2022.
Iwamoto SJ, Defreyne J, Rothman MS, et al. Health considerations for transgender women and remaining unknowns: a narrative review. Ther Adv Endocrinol Metab 2019 ; 10 : 2042018819871166.
Glintborg D, T’Sjoen G, Ravn P, Andersen MS. Management of endocrine disease: Optimal feminizing hormone treatment in transgender people. Eur J Endocrinol 2021; 185 : R49–R63.
https://ansm.sante.fr/actualites/androcur-acetate-de-cyproterone-et-generiques-risque-de-meningiome-lors-dune-utilisation-prolongee.
Burinkul S, Panyakhamlerd K, Suwan A, et al. Anti-Androgenic Effects Comparison Between Cyproterone Acetate and Spironolactone in Transgender Women: A Randomized Controlled Trial. J Sex Med 2021; 18 : 1299–307.
Irwig MS. Is there a role for 5’-reductase inhibitors in transgender individuals? Andrology 2021; 9 : 1729–31.
Patel KT, Adeel S, Miragaya JR, Tangpricha V. Progestogen Use in Gender Affirming Hormone Therapy: A Systematic Review. Endocr Pract 2022 : S1530–891X(22)00600–0.
Iwamoto SJ, T’Sjoen G, Safer JD, et al. Letter to the Editor: “Progesterone Is Important for Transgender Women’s Therapy-Applying Evidence for the Benefits of Progesterone in Ciswomen”. J Clin Endocrinol Metab 2019 ; 104 : 3127–3128.
Nolan BJ, Frydman AS, Leemaqz SY, et al. Effects of low-dose oral micronised progesterone on sleep, psychological distress, and breast development in transgender individuals undergoing feminising hormone therapy: a prospective controlled study. Endocr Connect 2022; 11 : e220170.
de Blok CJM, Dijkman BAM, Wiepjes CM, et al. Sustained Breast Development and Breast Anthropometric Changes in 3 Years of Gender-Affirming Hormone Treatment. J Clin Endocrinol Metab 2021; 106 : e782–90.
Klaver M, de Blok CJM, Wiepjes CM, et al. Changes in regional body fat, lean body mass and body shape in trans persons using cross-sex hormonal therapy: results from a multicenter prospective study. Eur J Endocrinol 2018 ; 178 : 163–171.
Van Caenegem E, Taes Y, Wierckx K, et al. Low bone mass is prevalent in male-to-female transsexual persons before the start of cross-sex hormonal therapy and gonadectomy. Bone 2013 ; 54 : 92–97.
Verroken C, Collet S, Lapauw B, T’Sjoen G. Osteoporosis and Bone Health in Transgender Individuals. Calcif Tissue Int 2022; 110 : 615–23.
Getahun D, Nash R, Flanders WD, et al. Cross-sex Hormones and Acute Cardiovascular Events in Transgender Persons: A Cohort Study. Ann Intern Med 2018 ; 169 : 205–213.
Streed CG, Jr, Harfouch O, Marvel F, et al. Cardiovascular Disease Among Transgender Adults Receiving Hormone Therapy: A Narrative Review. Ann Intern Med 2017 ; 167 : 256–267.
Maraka S, Singh Ospina N, Rodriguez-Gutierrez R, et al. Sex Steroids and Cardiovascular Outcomes in Transgender Individuals: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 2017 ; 102 : 3914–3923.
Nota NM, Wiepjes CM, de Blok CJM, et al. Occurrence of Acute Cardiovascular Events in Transgender Individuals Receiving Hormone Therapy. Circulation 2019 ; 139 : 1461–1462.
Totaro M, Palazzi S, Castellini C, et al. Risk of Venous Thromboembolism in Transgender People Undergoing Hormone Feminizing Therapy: A Prevalence Meta-Analysis and Meta-Regression Study. Front Endocrinol (Lausanne) 2021; 12 : 741866.
Cocchetti C, Castellini G, Iacuaniello D, et al. Does Gender-Affirming Hormonal Treatment Affect 30-Year Cardiovascular Risk in Transgender Persons? A Two-Year Prospective European Study (ENIGI). J Sex Med 2021; 18 : 821–9.
van Velzen DM, Adorni MP, Zimetti F, et al. The effect of transgender hormonal treatment on high density lipoprotein cholesterol efflux capacity. Atherosclerosis 2021; 323 : 44–53.
Islam N, Nash R, Zhang Q, et al. Is There a Link Between Hormone Use and Diabetes Incidence in Transgender People? Data From the STRONG Cohort. J Clin Endocrinol Metab 2022; 107 : e1549–57.
de Blok CJM, Wiepjes CM, Nota NM, et al. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ 2019; 365 : l1652.
Baraban E, Ding CC, White M, et al. Prostate Cancer in Male-to-Female Transgender Individuals: Histopathologic Findings and Association With Gender-affirming Hormonal Therapy. Am J Surg Pathol 2022 Aug 26. doi: 10.1097/PAS.0000000000001964.
Cocchetti C, Romani A, Collet S, et al. The ENIGI (European Network for the Investigation of Gender Incongruence) Study: Overview of Acquired Endocrine Knowledge and Future Perspectives. J Clin Med 2022; 11 : 1784.
Taub RL, Ellis SA, Neal-Perry G, et al. The effect of testosterone on ovulatory function in transmasculine individuals. Am J Obstet Gynecol 2020; 223 : 229.e1-8.
Mancini I, Alvisi S, Gava G, et al. Contraception across transgender. Int J Impot Res 2020; 33 : 710–9.
Baker KE, Wilson LM, Sharma R, et al. Hormone Therapy, Mental Health, and Quality of Life Among Transgender People: A Systematic Review. J Endocr Soc 2021; 5 : bvab011.
Bultynck C, Pas C, Defreyne J, et al. Self-perception of voice in transgender persons during cross-sex hormone therapy. Laryngoscope 2017 ; 127 : 2796–2804.
Irwig MS, Childs K, Hancock ABEffects of testosterone on the transgender male voice. Andrology 2017 ; 5 : 107–112.
Scharff M, Wiepjes CM, Klaver M, et al. Change in grip strength in trans people and its association with lean body mass and bone density. Endocr Connect 2019 ; 8 : 1020–1028.
Vita R, Settineri S, Liotta M, et al. Changes in hormonal and metabolic parameters in transgender subjects on cross-sex hormone therapy: A cohort study. Maturitas 2018 ; 107 : 92–96.
Tebbens M, Nota NM, Liberton NPTJ, et al. Gender-Affirming Hormone Treatment Induces Facial Feminization in Transwomen and Masculinization in Transmen: Quantification by 3D Scanning and Patient-Reported Outcome Measures. J Sex Med 2019 ; 16 : 746–754.
Wiepjes CM, den Heijer M, T’Sjoen GGBone health in adult trans persons: an update of the literature. Curr Opin Endocrinol Diabetes Obes 2019 ; 26 : 296–300.
Wiepjes CM, Vlot MC, Klaver M, et al. Bone Mineral Density Increases in Trans Persons After 1 Year of Hormonal Treatment: A Multicenter Prospective Observational Study. J Bone Miner Res 2017 ; 32 : 1252–1260.
Pirtea P, Ayoubi JM, Desmedt S, T’Sjoen G. Ovarian, breast, and metabolic changes induced by androgen treatment in transgender men. Fertil Steril 2021; 116 : 936–42.
Madsen MC, van Dijk D, Wiepjes CM, et al. Erythrocytosis in a Large Cohort of Trans Men Using Testosterone: A Long-Term Follow-Up Study on Prevalence, Determinants, and Exposure Years. J Clin Endocrinol Metab 2021; 106 : 1710–7.
Defreyne J, Vantomme B, Van Caenegem E, et al. Prospective evaluation of hematocrit in gender-affirming hormone treatment: results from European Network for the Investigation of Gender Incongruence. Andrology 2018 ; 6 : 446–454.